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Background
The therapeutic efficacy of nevirapine (NVP) is ham-
pered by its poor solubility; poor ability to target
infected cells and inherent toxicity. The objective of the
present study was surface functionalization with a new
targeting ligand to enable enhanced efficacy.
Methods
Surface functionalization of GMS nVP auNPs was stu-
died by fluroscence spectrophotometry. Nanoformula-
tions and NVP were evaluated for cytotoxicity at 1, 2
and 24 hours and uptake study at 0.5, 1 and 2 hours. In
vitro anti-HIV activity was evaluated in TZM bl cell line
against HeLa/LaV virus.
Results
GMS nVP auNPs with > 75% entrapment efficiency & <
300nm particle size were prepared and surface modified
nanoparticles showed >85% binding to the ligand. In cyto-
toxicity study nanoformulations showed higher cell viabi-
lity at all time points as compared to NVP. Cell uptake
study revealed higher uptake of nanoparticles as compared
to NVP only. In vitro anti HIV assay of surface modified
revealed 10 fold increased activity as compared to NVP.
Conclusion
Nanosize and surface functionalization both play an
important role in enhancing anti HIV potential of GMS
nVP auNPs.
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